favor drag
 rais focu newco out-year growth
result gener favor ep our/con est strong top-line
favor mix strong skyrizi psoriasi launch howev product-level
guidanc mix bad faster expect hcv eros slow
orilissa endometriosi launch good imbruvica gain point share
front-lin cll market skyrizi guid bump
make modest chang sale ep respect
beyond notabl model chang conserv us humira eros
post biosimilar entri declin prior first yr base
model project sale compound-annual-growth-rate vs stand-alon
reiter neutral limit catalyst rais po prior model chang
takeaway call
takeaway skyrizi psoriasi uptak note launch
skyrizi captur play share psoriasi vs humira
defin new switch patient skyrizi volum came
competitor biolog ex-humira management note leverag humira
payer facilit skyrizi launch cite y/i price benefit us humira
upadacitinib rheumatoid arthriti fda review management concern
drug approv lieu lack fda adcom believ upa pend launch
could replic skyrizi earli commerci success base strong product profil
today fda updat add thromboembol te risk pfizer xeljanz note
upa shown similar safeti concern blackbox around te risk difficult
predict believ outcom would base pm fda decis move
class label safeti risk us drug price legisl management support
bipartisan drug price bill note patient cost lower spread-
year note legisl hurdl could water
propos abbv exposur mpd current focus
part management believ conceiv pilot program could expand part
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
research-bas global pharmaceut
busi spun abbott
develop market drug area
immunolog virolog oncolog
rate neutral growth new
product launch balanc competit headwind
 see limit upsid consensu risa sale
forecast use limit psoriasi
indic next sever year
numer novel biolog competitor similar
valu proposit stock impact venclexta
upsid limit due partnership econom
orilissa upsid possibl would repres
fraction pend loe exposur
price object po base blend valuat risk-adjust
dcf pro forma entiti ev/ebitda multipl pro forma non-
gaap ep estim ev/ebitda multipl peer given modest
growth prospect assum wacc termin growth rate
pro forma entiti believ dcf assumpt reason minim
contribut pipelin valid late-stag clinic
downsid risk earlier-than-anticip launch humira biosimilar us
 integr risk clinic pipelin failur risk pend
transact
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
